Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

102 clinical studies listed.

Filters:

Gynecologic Cancer

Tundra lists 102 Gynecologic Cancer clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

COMPLETED

NCT05185947

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

Background: Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. In most cases, outcomes are poor. Researchers want to test a new treatment. Objective: To learn if the combination of oral nilotinib plus paclitaxel given by intravenous (IV) and directly into the abdomen can reduce tumors enough for people to have surgery. Eligibility: Adults aged 18 and older with peritoneal carcinomatosis that is too widespread for surgery. Design: Participants will be screened with: Physical exam Medical history Blood and urine tests Electrocardiogram Laparoscopy. They will get general anesthesia. Small cuts will be made in their abdomen. Tissue and fluid samples will be taken. Surveys about their health Computed tomography (CT) scans of their torso Participants will have up to 4 more laparoscopies. During the first procedure, a port will be placed under the skin of their abdomen (an intraperitoneal (IP) port). It will be attached to a catheter that is placed in their abdomen. Participants will get treatment in 3-week cycles, for 3 or 6 cycles. They will take nilotinib by mouth twice daily. They will get paclitaxel by IP port (once per cycle) and by IV (twice per cycle). After cycles 3 and 6, they will have a laparoscopy and CT scans. Then they may take nilotinib and get IV paclitaxel for up to 1 year. At study visits, participants will repeat some screening tests. About 6 weeks after treatment ends and then every 3 months for 3 years, participants will have follow-up visits at National Institutes of Health (NIH) or with their local doctor.

Gender: All

Ages: 18 Years - Any

Updated: 2026-05-29

1 state

Gynecologic Cancer
Gynecologic Neoplasms
Peritoneal Carcinomatosis
+9
COMPLETED

NCT05044975

Improving Sleep in Gynecologic Cancer Survivors

This purpose of this study is to learn about how to provide treatment to gynecologic cancer survivors who have difficulty sleeping.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-05-22

2 states

Sleep Disturbance
Gynecologic Cancer
ACTIVE NOT RECRUITING

NCT04007770

Acupuncture Pilot Study for Cancer-related Cognitive Function

This study is being done to explore whether acupuncture can improve cognitive difficulties in patients diagnosed with cancer.

Gender: All

Ages: 18 Years - Any

Updated: 2026-05-22

2 states

Stage I Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer
+10
RECRUITING

NCT07398079

Pilot Observational Study of an Integrative Cure Stay Program

This pilot observational study evaluates the feasibility and acceptability of conducting a prospective study alongside the individualized integrative oncology cure stay program "Via Shalva" for breast and gynecological cancer survivors. The study further explores preliminary changes in patient-reported outcomes, physiological measures, and biological markers before and after the retreat and compared with a matched control group.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-05-22

Breast Cancer
Gynecologic Cancer
RECRUITING

NCT06673329

Brodalumab in the Treatment of Immune-Related Adverse Events

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to closely mirror these autoimmune conditions. Brodalumab has not been approved by the United States Food and Drug Administration (FDA) for use in immunotherapy side effects but it has been approved for treatment of autoimmune conditions.

Gender: All

Ages: 18 Years - Any

Updated: 2026-05-13

1 state

Breast Cancer
Esophageal Cancer
Kidney Cancer
+15
NOT YET RECRUITING

NCT07502157

Massage, Oncology, Pain, Anxiety, Feasibility

The goal of this clinical trial is to determine the feasibility of studying massage therapy in patients with gynecologic cancers while receiving infusion treatments. The central hypothesis is that it is feasible to implement a massage intervention study in an infusion center at an academic hospital, and measure pain and anxiety in patients with gynecological cancer. The main questions it aims to answer are: Can investigators evaluate feasibility to conduct a study from a design standpoint? Can investigators assess the use of randomization, blinding of assessors, potential to control the study with an attention group, and recruitment/retention processes? Can investigators successfully collect outcome measures of pain and anxiety, pre/post intervention? Researchers will investigate degree of resources needed, such as massage therapists, assessors, and timing of delivery intervention. Assess positive/negative effects on target population determining massage modality and anatomical location. Researchers will compare massage therapy to an attention control group, to see if massage therapy works to treat pain and anxiety in patients with cancer. Establish variability in outcome measures. Participants will: Be randomized and receive either massage therapy or attention control over the course of three consecutive infusion therapy treatments. Each infusion therapy treatment occurs every 2-4 weeks.

Gender: FEMALE

Ages: 18 Years - 85 Years

Updated: 2026-05-11

1 state

Gynecologic Cancer
ACTIVE NOT RECRUITING

NCT04753086

Patient Related Outcomes for Gynecologic Radiation Oncology

The goal of this study is to see if it is feasible to use electronic questionnaires to measure patient related outcomes before, during, and after radiation for gynecologic cancer in a high-volume radiation oncology clinic.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-05-04

1 state

Gynecologic Cancer
RECRUITING

NCT05726136

Fluid Challenge and Plasma Volume, During Surgery

A short bolus infusion of fluid, called "fluid challenge" is commonly recommended for fluid treatment during longer surgery. However a prolonged increase of the blood volume is a prerequisite to recommend the technique. The purpose with the study is to examine the plasma expanding effect of three different fluid challenge strategies (acetated Ringers 4 ml/kg body weight, albumin 5% 4 ml/kg body weight or albumin 20% 1 ml/kg body weight), using hemoglobin as a dilution indicator.

Gender: All

Ages: 18 Years - 85 Years

Updated: 2026-04-30

1 state

Colorectal Cancer
Urologic Cancer
Gynecologic Cancer
+2
RECRUITING

NCT07558889

The Surveillance, Epidemiology, and End Results Database Program on Endometrial Cancer in the Italian Population

The aim of this study is to lay the bases for an ambitious project that reports and records all the epidemiological-clinical information of the cases of endometrial carcinoma diagnosed and treated in the reference oncology centers involved on the national territory, to create a process of analysis of the data

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-04-30

Endometrium Cancer
Gynecologic Cancer
RECRUITING

NCT07296887

CARE Tool Study Aim 3

This study is a multi-site randomized trial to study the implementation of the CARE Tool and evaluate the CARE Tool. The CARE Tool is a web-based tool that gives people information about cancer care costs, health insurance, and resources to help with costs. Overall, the study aims to help patients with cancer overcome barriers they face navigating insurance and accessing financial resources.

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-30

2 states

Gynecologic Cancer
Prostate Cancer
Lung Cancer
+1
RECRUITING

NCT06936878

BOLSTER: Learning New Skills to Thrive

This research study is evaluating a new program called Building Out Lifelines for Safety, Trust, Empowerment, and Renewal or (BOLSTER), which was designed to support participants with a gynecological or gastrointestinal cancer and new and complex care needs.

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-28

2 states

Gastrointestinal Cancer
Gynecologic Cancer
Advanced Cancer
ACTIVE NOT RECRUITING

NCT05509751

The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person

Phase 2 randomized controlled study using a waitlist control group. The study also has a single arm pre-post test 12-week chair-based exercise arm for those who have received the geriatric assessment in the older adults with cancer clinic (geriatric oncology clinic). Study Duration 2.5 years Study Agent/ Intervention/ Procedure Comprehensive Geriatric Assessment and Management (GAM) combined with online chair-based exercise (CBE) and health education for 12 weeks.

Gender: All

Ages: 65 Years - Any

Updated: 2026-04-28

1 state

Lung Cancer
Gastro-intestinal Cancer
Genito-Urinary Cancer
+3
RECRUITING

NCT06728709

Lung Ultrasound in Critically Ill Obstetrics and Gynecological Patients

Pulmonary dysfunction aggravates the illness of critically ill obstetrics and gynecological patients. Early identification with bedside technique and prompt management may improve the outcome of critical care in this vulnerable population

Gender: FEMALE

Updated: 2026-04-22

1 state

Obstetric Complication
Gynecologic Cancer
Lung Diseases
+1
ACTIVE NOT RECRUITING

NCT03970083

A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer

This research is studying the level of oxygen in tumors during the brachytherapy procedure.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-04-22

1 state

Gynecologic Cancer
Cervical Cancer
ACTIVE NOT RECRUITING

NCT03277469

Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer

The aim of this study is to develop new tools using magnetic resonance imaging (MRI) that will improve the brachytherapy procedure and treatment for participants with gynecologic cancer.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-04-22

1 state

Gynecologic Cancer
RECRUITING

NCT05559879

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of antigen presentation. In this study, Cabozantinib (VEGF inhibitor) and Dostarlimab (immunotherapeutic drug) will be admnistered as a combination to patients with recurrent gynecologic carcinosarcoma.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-04-15

1 state

Gynecologic Cancer
Carcinoma
Uterine Cancer
+1
RECRUITING

NCT05313191

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

The goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy. Generally, when patients are first treated for cancer with radiation therapy, they are treated with traditional photon (or x-ray) radiation therapy, which uses high-energy waves to kill tumor cells. In some cases, the cancer either returns or a new tumor can present in a different part of the body. With the usual radiation treatment, the photon beams travel all the way through the body. As a result, healthy tissues in front of and behind the tumor are exposed to radiation. Physicians who treat these cases where the tumor has returned often use a much lower dose of radiation to prevent patients from experiencing serious and long-term side-effects. This dose is often not strong enough to destroy the cancerous tumor. Alternatively, they may also treat a smaller area than would be indicated for complete tumor eradication, again in an attempt to prevent serious and long-term toxicities, but at the cost of optimally treating the cancer. Proton therapy, however, may offer a chance to safely deliver a more effective dose and volume of radiation as it is more targeted and can spare healthy tissues surrounding the tumor. The reason we are conducting this research study is to look at whether Proton therapy can be a better way to treat reoccurring tumors in patients who have previously received radiation therapy to the same area, compared to treatment approaches used to date.

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-13

1 state

CNS Cancer
Head and Neck Cancer
GI Cancer
+4
ACTIVE NOT RECRUITING

NCT06342986

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

This is a single center Phase I clinical trial of FT536 administered intraperitoneally (IP) 3 times a week for one week for the treatment of recurrent gynecologic cancers. A short course of outpatient lymphodepleting chemotherapy is given prior to the first dose of FT536 to promote adoptive transfer.

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-02

1 state

Gynecologic Cancer
Ovarian Cancer
Fallopian Tube Cancer
+1
ACTIVE NOT RECRUITING

NCT04893434

Novel Imaging Technique to Assess Gynecologic Cancer

This study will test a new type of DCE (dynamic contrast-enhanced) MRI (magnetic resonance imaging) to see whether, compared with traditional MRI, it produces better images that provide more information about tumors, which may help doctors make better decisions about treating women who have gynecologic cancer. MRI is commonly used to detect and evaluate many types of cancer, but its slow processing speed and the risk that images will be blurred if the patient moves inside the scanner can limit its use in clinical practice. DCE MRI is a new imaging technique that uses additional computer processing to collect information continuously during scanning, which produces more detailed images faster than traditional MRI, which reduces the risk of movement-related blurring and provides important information about tumor activity. The DCE MRI scan in this study will be done in a standard MRI scanner, using a contrast agent (gadobutrol; Gadavist®) that has been approved by the FDA.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-04-02

2 states

Gynecologic Cancer
RECRUITING

NCT05142033

Avera Cancer Sequencing and Analytics Protocol (ASAP)

The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant and malignant conditions across a range of disease stages and cancer types. Comprehensive molecular profiling will include somatic tumor testing (tissue and/or blood) using next-generation sequencing. Selected subsets of samples may undergo whole exome and/or whole transcriptome sequencing for research purposes. Pharmacogenomic testing will also be performed to better understand individual variability in medication response and to identify opportunities for optimizing treatment. In addition, participants may optionally provide microbiome samples. To maximize the value of the genomic data, participants who consent to this protocol will have their electronic health records-both retrospective and prospective-abstracted, curated, annotated, and linked to the genomic data generated through study testing. Given the long-term value of these data, participants may also voluntarily consent to the storage of their biological samples in a biobank and to the use of their de-identified information for future research. Data collected from this participant population will support efforts to advance the understanding of cancer biology, as well as the discovery and validation of biomarkers associated with clinical outcomes. Findings may also be shared through collaborative research initiatives to further promote advancements in cancer research.

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-27

2 states

Cancer
Cancer Diagnosis
Early Detection of Cancer
+9
ACTIVE NOT RECRUITING

NCT05980169

The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy

The goal of this clinical trial is to assess the efficacy of SensoniQ® Treatment Station in preventing or reducing chemotherapy induced peripheral neuropathy symptoms (CIPNS) in patients receiving frontline carboplatin and paclitaxel chemotherapy for a gynecologic malignancy. This study will also assess the improvement of CIPNS in patients who have previously received carboplatin and paclitaxel therapy with persistent Grade 2 or worse neuropathy. The main questions this clinical trial aims to answer are: 1. To investigate the efficacy of SensoniQ® Treatment Station on the prevention or reduction of CIPNS in gynecologic oncology patients receiving front line carboplatin and paclitaxel. 2. To investigate the efficacy of SensoniQ® Treatment Station on the improvement of existing CIPNS in patients who previously received chemotherapy with platinum agent and paclitaxel for a gynecologic malignancy

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-03-23

1 state

Gynecologic Cancer
Neuropathy;Peripheral
ACTIVE NOT RECRUITING

NCT05677048

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

This is a community-based study requiring participant-self-enrollment, that can help to increase the rates of genetic testing among the family members of people who have been diagnosed with a hereditary cancer syndrome. The two main factors in this study are the IGNITE-TX intervention (website and navigator) and the free genetic counseling and testing. The IGNITE-TX Intervention is an innovative multi-modal intervention, with two components: a) interactive web "IGNITE-TX Hub" and b) genetic family navigators.

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-09

1 state

Gynecologic Cancer
Ovary Cancer
Pancreatic Cancer
+6
RECRUITING

NCT04075305

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-05

5 states

Oncology
Breast Cancer
Prostate Cancer
+35
RECRUITING

NCT06746428

Activity Coaching During Pelvic Radiation Therapy

Research has shown that for women who are undergoing pelvic radiation therapy, fatigue is a common side effect. Fatigue that occurs during radiation therapy can make it harder to perform daily living activities. While there are studies that recommend exercise as a treatment for fatigue in cancer patients and survivors, there are currently no studies that focus on the role of exercise for women undergoing pelvic radiation therapy. The purpose of this study is to see if incorporating an activity coaching program is helpful in improving treatment-related fatigue for women undergoing pelvic radiation therapy for endometrial cancer.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-03-03

1 state

Radiation Therapy
Gynecologic Cancer
Exercise Therapy